Roivant's dermatomyositis drug Lisraya snags FDA approval
The FDA approved Roivant’s dermatomyositis drug brepocitinib on Wednesday, the first major regulatory nod that could usher in a multibillion revenue stream for the hub-and-spoke pharma. The drug, marketed as Lisraya, is the first oral ...
Roivant CEO Matt Gline August 27, 2026 05:27 PM EDT R&DPharma Roivant’s road to a potential blockbuster begins with Lisraya FDA approval Max Bayer Senior Reporter The FDA approved Roivant’s dermatomyositis drug brepocitinib on Wednesday, the first major regulatory nod that could usher in a multibillion revenue stream for the hub-and-spoke … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that